{
    "2019-02-01": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Cramer's game plan: Be ready to 'buy the next dip' in this 'ideal backdrop for stocks'",
                "features": {
                    "keywords": [
                        "buy",
                        "next dip",
                        "ideal backdrop",
                        "stocks"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva",
                "features": {
                    "keywords": [
                        "insurer",
                        "Amgen",
                        "Eli Lilly",
                        "migraine drugs",
                        "Teva"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Q4",
                        "Earnings Miss",
                        "Revenues Beat"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY",
                "features": {
                    "keywords": [
                        "ETF Inflow",
                        "XLV",
                        "AMGN",
                        "ABBV",
                        "LLY"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ETFs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Lilly (LLY) Hits 52-Week High, Can the Run Continue?",
                "features": {
                    "keywords": [
                        "Lilly",
                        "52-Week High",
                        "Run Continue"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY",
                "features": {
                    "keywords": [
                        "Pharma Stock",
                        "Q4 Earnings",
                        "Pipeline Updates",
                        "PFE",
                        "RHHBY"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Pharma Catches Another Case Of M&A Fever",
                "features": {
                    "keywords": [
                        "Pharma",
                        "M&A Fever"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant",
                "features": {
                    "keywords": [
                        "Biotech Pulse",
                        "Merck",
                        "Earnings",
                        "Titan",
                        "Opioid Disorder",
                        "Treatment Implant"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Loxo Oncology",
                        "HSR Act",
                        "Waiting Period",
                        "Transaction"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study",
                "features": {
                    "keywords": [
                        "J&J",
                        "Erleada",
                        "Primary Endpoints",
                        "Late-Stage Study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}